2015 American Transplant Congress » Concurrent Session: Kidney: Novel Agents

4:00pm-4:12pm

Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated With Belatacept

W. Kitchens,¹ A. Farris,² S. Pastan,¹ T. Pearson,¹ C. Larsen,¹ A. Adams.¹

4:12pm-4:24pm

Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT

R. Bray,¹ H. Gebel,¹ R. Townsend,² U. Meier-Kriesche,² C. Larsen.¹

4:24pm-4:36pm

Final Results from the BENEFIT-EXT Trial: A 7 Year Follow-Up of Belatacept Treated Patients

S. Florman,¹ J. Medina Pestana,² M. Rial,³ L. Rostaing,⁴ D. Kuypers,⁵ F. Mühlbacher,⁶ M. Polinsky,⁷ U. Meier-Kriesche,⁷ J. Grinyó,⁸ A. Durrbach.⁹

4:36pm-4:48pm

CFZ533: Assessment of Immunomodulatory Activity Following Single Doses of a Novel Anti-CD40 mAb in Healthy Volunteers

A. Slade,¹ J. Doucet,² P. Koo,¹ P. Espie,² J. Rush,² C. Tomek,³ J. Klupp.²

4:48pm-5:00pm

Induction of a Costimulation-Susceptible Repertoire: A Case for Depletional Prior to Belatacept

H. Xu,¹ K. Samy,¹ A. Guasch,² S. Mead,² A. Kirk.¹

5:00pm-5:12pm

Clinical and Pathologic Predictors of Response to Belatacept Conversion

S. Patel, H. Morris, D. Cohen, S. Mohan, L. Ratner, R. Crew.

5:12pm-5:24pm

Belatacept Based Immunosuppression and Incidence of Proteinuria in Kidney Transplant Recipients

R. Villicana, A. Peng, J. Kahwaji, J. Choi, A. Vo, S. Jordan.